Concepedia

Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial

George J. Kahaly, Michaela Riedl, J. König, Susanne Pitz, Katharina A. Ponto, Tanja Diana, Elena Kampmann, E. W. Kolbe, Anja Eckstein, Lars C. Moeller,

The Lancet Diabetes & Endocrinology · 2018 · 216 citations · 20 references

DOI

Concepts

References

20

PLACEBO-CONTROLLED STUDY OF MYCOPHENOLATE MOFETIL COMBINED WITH CYCLOSPORINE AND CORTICOSTEROIDS FOR PREVENTION OF ACUTE REJECTION

Josep M. Grinyó, CG Groth, R. Pichlmayr et al. · Data Archiving and Networked Services (DANS) · 1995 · 979 citations

, , +9

The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy

Luigi Bartalena, Lelio Baldeschi, Kostas Boboridis et al. · European Thyroid Journal · 2016 · 954 citations · Full text

, , +11

Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection

The Lancet · 1995 · 933 citations

, , +15

Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO

Luigi Bartalena, Lelio Baldeschi, Alison Dickinson et al. · European Journal of Endocrinology · 2008 · 797 citations

, , +10

Thyrotropin Receptor Autoantibodies Are Independent Risk Factors for Graves’ Ophthalmopathy and Help to Predict Severity and Outcome of the Disease

Anja Eckstein, Marco Plicht, Hildegard Lax et al. · The Journal of Clinical Endocrinology & Metabolism · 2006 · 480 citations

, , +17